Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure; Coronary artery disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 13 Sep 2017 Planned End Date changed from 7 Sep 2017 to 16 Oct 2017.
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.